KENDYL COLEMAN: Open Payments
NPI 1447838701 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,213 in 92 payments from 30 companies in 2025. Trend: 2023 $5,385 · 2024 $2,419 · 2025 $2,213
Food & beverage: $2,213
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $340 |
| Biogen, Inc. | 7 | $290 |
| EMD Serono, Inc. | 8 | $213 |
| Novartis Pharmaceuticals Corporation | 17 | $196 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| ARGENX US, INC. | 3 | $77 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| UCB, Inc. | 2 | $71 |
| PFIZER INC. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
Products named: QULIPTA, TYSABRI, KESIMPTA, ZEPOSIA, UBRELVY, LEQEMBI, REXULTI, VYVGART HYTRULO.
Industry payments across GA — which companies pay providers there.
